You are here: Home » Current Affairs » News » National
Business Standard

Ambassadors of 100 countries to visit Serum Institute, Gennova Biopharma

Sweden seeks to expand ties with India in health and life sciences, Luxembourg-based firm B Systems is partnering with India to produce portable vaccine refrigeration equipment

Topics
Coronavirus | Serum Institute of India | Health sector

Ruchika Chitravanshi  |  New Delhi 

Photo: Abhishek Waghmare
In his online interaction with vaccine developers, Modi asked the companies to come out with their suggestions and ideas regarding the regulatory processes | Photo: Abhishek Waghmare

Ambassadors of one hundred countries are scheduled to arrive in Pune on December 4, to visit and Gennova Biopharma, a press statement by the Prime Minister’s Office said.

Serum Institute in Pune would be undertaking mass production of Covishield vaccine developed by Oxford–Astra Zeneca.

While Sweden is looking to expand bilateral cooperation in the areas of health and life sciences in view of the pandemic with India, Luxembourg based company B Systems is partnering with India to produce portable vaccine refrigeration equipment, the press statement said.

Prime Minister Narendra Modi had visited its facility and also those of Zydus Biotech Park in Ahmedabad and Bharat Biotech in Hyderabad on Saturday to take stock of vaccine preparedness in the country.

Modi took a virtual review of progress of indigenous vaccine development undertaken by Gennova Biopharma of Pune and Biological E and Dr Reddy’s Laboratories in Hyderabad on Monday.

The government had recently allocated Rs 900 Crore for ‘Mission Covid Suraksha’ to the department of biotechnology for research and development to promote indigenous vaccine development. “A total of 10 vaccine candidates have been supported by the Department of Biotechnology so far at both academia and industry and as on date, five vaccine candidates are in human trials stage.”

In his online interaction with vaccine developers, Modi asked the companies to come out with their suggestions and ideas regarding the regulatory processes and related matters. He also suggested that they should take extra efforts to inform the general public in simple language about the vaccine and related matters such as its efficacy.

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Mon, November 30 2020. 18:56 IST
RECOMMENDED FOR YOU
.